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Purpose: The aim of this study was to report management and
outcomes in patients affected by eyelids carcinomas involving
regional lymph nodes.
Methods: We have retrospectively analyzed the data of patients
affected by eyelids carcinoma with nodal involvement. The clinical
records of 10 patients with malignant eyelid carcinoma and regional
nodal metastasis treated between September 2011 and March 2015
have been analyzed.
Results: The study included 5 women and 5 men (median age 54,5
years; range 37–80 years). The most common tumor was the
squamous cell carcinoma (4 cases) followed by sebaceous carci-
noma (2 cases): 1 case of epidermoid carcinoma, 1 case of malig-
nant melanoma, 1 case ofMerkel carcinoma, and 1 case of basal cell
carcinoma. All patients were treated by surgical resection; in 2
cases, orbital exenteration was required. The treatment of regional
nodal metastasis consisted of parotidectomy and radical neck
dissection followed by radiation therapy. None of the patients
developed local recurrence. Three patients died: one, affected by
Merkel cell carcinoma, died after 2 months because of metastatic
dissemination to the lung; another one, affected by epidermoid
carcinoma involving the orbit, died because of liver metastasis; the
third one, affected by malignant melanoma, died because of other
causes. The follow-up time ranged from 9 to 36 months (median
19.3 months).
Conclusions: Patients affected by advanced malignant eyelid car-
cinoma need to be strictly controlled because metastasis can
develop at least 5 years after surgical treatment. Therapy may
include a combination of local surgery, neck dissection, and
radiation.
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he incidence of eyelid carcinomas is estimated to be in the
1TABLE 1. Patient and Tumor Characteristics
Median age (range), y 54.5 (37–80)
Location
Upper eyelid 6 (60%)T literature 5% to 10% of all cutaneous tumors. The most
frequent are the epithelial tumors, represented by the basal cell
carcinoma (BCC), squamous cell carcinoma (SCC), and sebaceous
carcinoma (SebCa). The most frequent non-epithelial tumors are
melanoma of the eyelid, and Merkel cell carcinoma (MCC).
The BCC accounts for 86% to 96% of all eyelid tumors, SCC
accounts for 3.4% to 12.6%, SebCa accounts for 0.6% to 10.2%, and
melanoma and MCC account for <1% of all eyelid tumors.1–3Copyright © 2017 Mutaz B. Habal, MD. Unautho
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The Journal of Craniofacial Surgery  Volume 00, Number 00, MThe criterion standard treatment is represented by the surgical
removal of the primary lesion with negative margins eventually
followed by local flaps for reconstruction.
Unfortunately, some cases require the orbital exenteration. In
case of aggressive lesion that metastasizes to the regional lymph
nodes, the therapy consists in total parotidectomy and neck dis-
section. Herein we report our experience in the management of
metastatic eyelid carcinoma.
MATERIALS AND METHODS
The clinical records of these patients with advanced malignant
eyelid carcinoma and nodal metastasis, treated between September
2011 and March 2015 at University of Naples Federico II, Head and
Neck Department, have been evaluated.
The study included 5 women and 5 men (median age 54.5 years;
range 37–80 years). The most common tumor was the SCC (4
cases; 40%) followed by SebCa in 2 cases (20%), 1 case of
epidermoid carcinoma (10%), 1 case of malignant melanoma
(10%), 1 case of MCC (10%), and 1 case of BCC (10%). The
clinical examination included a complete adnexal and ocular exam-
ination, and the palpation of the lymph nodes of parotid and cervical
region. Patients and tumors characteristic are shown in Table 1. In
all patients, Doppler-ultrasonography of parotid, submandibular,
and cervical nodes was performed. All patients presented parotid
metastasis at the time of diagnosis confirmed with a fine-needle
aspiration biopsy (FNAB) (Fig. 1).
All patients underwent a computed tomography (CT) scan or
magnetic resonance imaging (MRI) examination of the orbit,
maxilla, salivary glands, and neck, to evaluate the ocular infiltration
and the regional nodal metastasis. Positron emission tomography
(PET)-CT scan of total body was performed to exclude distant
metastasis. The clinical tumor mode metastasis (TNM) is reported
in Table 2.
All patients were treated with radical surgery of the primary
tumor and frozen section to control the margins. The treatment of
regional nodal metastasis consisted of total parotidectomy with
nerve sparing, if there were not clinical signs of nerve involvement,
and radical neck dissection followed by radiation therapy. Our
research was approved by local institutional review board.
RESULTS
All 10 patients were treated by surgical resection of the tumor with
frozen section control of margins; in 2 cases, orbital exenteration
was required because of the orbital infiltration (1 case ofMCC and 1
case of epidermoid carcinoma). Symptoms of orbital involvement
were: exophthalmos, ocular motility deficit, and loss of vision.rized reproduction of this article is prohibited.
Lower eyelid 1 (10%)
Internal cantus 1 (10%)
External cantus 2 (20%)
Median tumor size (range), cm 1.8 (0.9–4)
Histological type
Squamous cell carcinoma 4 (40%)
Sebaceous carcinoma 2 (20%)
Epidermoid carcinoma 1 (10%)
Malignant melanoma 1 (10%)
Merkel carcinoma 1 (10%)
Basal cell carcinoma 1 (10%)
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Merkel c. T3bN1M0 IIIb þ II-III Levels
Epidermoid c. T3bN1M0 IIIb þ –
Basal cell c. T1N1M0 IIIb þ –
Malignant Melanoma T2aN1M0 IIIb þ –
Squamous cell c. T2aN1M0 IIIb þ –
Squamous cell c. T2bN1M0 IIIb þ –
Squamous cell c. T1N1M0 IIIb þ –
Squamous cell c. T2bN1M0 IIIb þ –
Sebaceous c. T1N1M0 IIIb þ I Level
c, carcinoma; TNM, tumor mode metastasis.
FIGURE 1. Patient affected by squamous cell carcinoma of the upper left eyelid
(A). Computed tomogrpahy scans examination of the same patient showing the
left eyelid lesion (B) and the nodal metastasis in his left parotid gland (C).
Postoperative photo of the patient after eyelid surgery, parotidectomy and
radical neck dissection followed by radiotherapy; frontal view (D). Lateral
view (E).
Brief Clinical Studies The Journal of Craniofacial Surgery  Volume 00, Number 00, Month 2017According with literature, for cutaneous malignancies arising on
the anterior and lateral part of the face, the treatment of regional
nodal metastasis consisted of total parotidectomy and radical neck
dissection (levels I–V).4,5
The pathological TNM and the staging are reported in Table 3.
Histopathological examination showed 30% of occult metastasis.
Radiation therapy was required in all cases, because of the extra
capsular involvement, nodal metastases, and perineural invasion.
One of these patients developed chronic dry eye and cataract, as side
effect of radiation.
The patients affected by MCC and epidermoid carcinoma
received also systemic chemotherapy because of distant metastasis
detected during follow-up PET-CT total body examination.
The disease-specific and overall survival rates for all patients
were 80% and 70%, respectively. None of the patients developed
local recurrence, but unfortunately the patients with MCC died afterCopyright © 2017 Mutaz B. Habal, MD. Unautho
TABLE 2. Clinical TNM
Merkel cell carcinoma T3bN1Mo
Epidermoid carcinoma T3bN1Mo
Basal cell carcinoma T2bN1Mo
Malignant melanoma T2aN1Mo
Squamous cell carcinoma T2aN1Mo
Squamous cell carcinoma T2bN1Mo
Squmous cell carcinoma T1N1Mo
Squamous carcinoma T2bN1Mo
Sebaceus cell carcinoma T1N1Mo
Sebaceus cell carcinoma T1N1Mo
TNM, tumor mode metastasis.
22 months from diagnosis because of metastatic dissemination to the
lung, and the patients affected by epidermoid carcinoma died after 9
months from diagnosis because of liver metastases. Also the patient
affected by malignant melanoma died because of a stroke.DISCUSSION
Malignant eyelid tumors seem to be easy to diagnose on the basis of
history and clinical signs and symptoms during the clinical exam-
ination, but sometimes malignant periocular skin lesions can mimic
benign pathology. For instance, a cystic BCC can resemble a
hidrocystoma; furthermore, sebaceous gland carcinoma classically
mimics a chalazion.
When thediagnosis and the treatment are delayed, orbital invasion
by periocular tumors can occur and should be suspected in case of
recurrent lesions with an orbital mass, globe displacement, limitation
of eye movement, numbness, and loss of vision. Therefore, a biopsy,
in case of suspicious lesions, is always recommended.
Perineural invasion worsens the prognosis, and sometimes is
followed by nodal involvement.6 The management of these lesions
is related to the histopathology and clinical stage, according to the
7th Edition for Eyelid Carcinoma Classification System from the
American Joint Committee on Cancer.4 In this retrospective study,
we report our experience on 10 patients affected by metastatic
carcinoma of the eyelid. The first site of metastasis was the parotid
gland in all 10 cases, followed by regional lymph nodes, levels I to
V detected only during the hystopathological examination (30%
micrometastasis). In one case we report distant metastasis to the
lung, and in another case to liver.
The management of eyelid carcinoma consists of complete
surgical excision of the primary lesion with margin control. In
case of aggressive lesion that metastasizes to the regional lymph
nodes, the therapy consists in total parotidectomy with nerve
sparing, if there is no sign of nerve involvement, and radical neck
dissection given that micro metastasis can occur.
We generally recommend adjuvant radiotherapy to regional
lymph nodes in presence of nodal involvement, extra capsular
infiltration, perineural invasion, or recurrent tumors.
The role of sentinel node biopsy has been recommended for
early detection of metastasis in regional lymph nodes but is outside
the aim of this study, and is widely described in the literature5,7,8,9
In the management of eyelid tumors, radiation has been used for
adjuvant treatment of high-risk carcinoma with perineural invasion,
or as primary treatment of advanced disease, or as palliative
treatment. Systemic chemotherapy (cyclophosphamide, methotrex-
ate, 5-fluorouracil, cisplatin, and etoposide) has been used in
patients with extensive nodal disease in patients affected by Merkel
carcinoma.10 Topical chemotherapy (including Imiquimod 5%rized reproduction of this article is prohibited.
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The Journal of Craniofacial Surgery  Volume 00, Number 00, Month 2017 Brief Clinical Studiescream, 5-fluorouracil eye drops, and Mitomycin C eye drops, and
interferon alpha-2 b eye drops) has been used as both primary and
adjuvant therapy for SebCa or SCC with a tumor control of 100% in
all the 4 cases treated.11
In case of metastatic or advanced carcinoma not eligible to
surgical excision or radiotherapy, targeted therapy against the
hedgehog pathway for BCC or epidermal growth factor receptor
for SCC seems to be a valid therapy to avoid the tumor pro-
gression.12
After the treatment of the eyelid carcinoma, it is important to
continue a strictly surveillance of the patient to exclude local
recurrence, or local and distant metastases. During each visit, the
surgical site and the neck should be carefully examined. In case of
cervical adenopathy, a Doppler sonography is recommended, and in
case a suspicious node is noted, an FNAB has to be performed.
Ophthalmological examination is recommended with the same
frequency, to detect recurrence on the conjunctival surface or in
the tarsal plate.
A CT scan or MRI of the head and neck region may be
appropriate, in addition to the careful clinical examination of the
patient during the follow-up period in case of relapse. A PET-CT
scan of total body for lung and liver metastases is appropriate for
advanced carcinoma. Most cases of nodal metastasis occur within
the first 2 to 3 years after treatment of carcinoma, and in some cases,
late metastasis can occur.13–14
CONCLUSIONS
In our experience, a radical surgery of the primary eyelid lesion,
associated with total parotidectomywith nerve sparing, if there is no
sign of nerve involvement, and radical neck dissection followed by
radiotherapy, in selected cases, is an effective treatment for nodal
invasion of the parotid glands and cervical lymph nodes.
Longer follow-up is necessary to assess the duration of
tumor control.
Patients with eyelid carcinoma need to be strictly controlled; the
frequency and the duration of the clinic controls are related on the
histology and on the stage of tumor. For BCC, SebCa, SCC,
melanoma, and MCC, at least a five year follow-up is required:
every 3 months during the first year, then every 6 months for the
other years. From the third year, the follow-up control is recom-
mended once per year.Copyright © 2017 Mutaz B. Habal, MD. Unautho
# 2017 Mutaz B. Habal, MDThe eyelid tumors need a careful management since a mis-
diagnosis, a nonradical surgery or an inappropriate follow-up, it
causes a high risk of metastases and the death of the patients.
REFERENCES
1. Yin VT, Merritt HA, Sniegowski M, et al. Eyelid and ocular surface
carcinoma: diagnosis and management. Clin Dermatol 2015;33:
159–169
2. Lin HY, Cheng CY, Hsu WM, et al. Incidence of eyelid cancers in
Taiwan: a 21-year review. Ophthalmology 2006;113:2101–2107
3. DeprezM, Uffer S. Clinicopathological features of eyelid skin tumors: a
retrospective study of 5504 cases and review of literature. Am J
Dermatopathol 2009;3:256–262
4. Ainbinder DJ1, Esmaeli B, Groo SC, et al. Introduction of the 7th
edition eyelid carcinoma classification system from the American Joint
Committee on Cancer-International Union Against Cancer staging
manual. Arch Pathol Lab Med 2009;133:1256–1261
5. Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for
metastatic sebaceous cell carcinoma of the eyelid. Dermatolo
2008;47:276–279
6. Rene C. Oculoplastic aspects of ocular oncology. Eye 2013;27:199–207
7. Leibovitch I, Selva D, Huigol S, et al. Intraepithelial sebaceous
carcinoma of the eyelid misdiagnosed as Bowen’s disease. J Cutan
Pathol 2006;33:303–308
8. Nijhawan N, Ross MI, Diba R, et al. Experience with sentinel lymph
node biopsy for eyelid and conjunctival malignancies at a cancer center.
Ophthalm Plast Reconstr Surg 2004;20:291–295
9. Herbst A, Haynes HA, Nghiem P. The standard of care for Merkel cell
carcinoma should include adjuvant radiation and lymph node surgery.
J Am Acad Dermatol 2004;46:640–642
10. Hata M, Koike I, Omura M. Noninvasive and curative radiation therphy
for sebaceus carcinoma of the eyelid. Int J Radiat Oncol Biol Phys
2012;82:605–611
11. Shields Cl, Naseripour M, Shields Ja, et al. Topical Mytomycin-C for
pagetoid invasion of conjuntiva by eyelid sebaceus gland carcinoma.
Ophthalmology 2002;109:2129–2133
12. Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and
periocular basal cell carcinoma and squamous cell carcinoma. Ophthal
Plast Reconstr Surg 2013;29:87–92
13. Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the
eyelids: personal experience with 60 cases. Ophthalmology
2004;111:2151–2157
14. Peters GB 3rd, Meyer DR, Shields JA, et al. Management and prognosis
of Merkel cell carcinoma of the eyelid. Ophthalmology 2001;108:
1575–1579rized reproduction of this article is prohibited.
3
